Results of the Phase I/II Study and Preliminary B-cell Gene Signature of Combined Inhibition of Glutamine Metabolism and EGFR in Colorectal Cancer
The combination of CB-839 and panitumumab showed safety and promising preliminary responses, but the study closed early due to CB-839 development termination. The B-cell activation signature "B-score" emerged as a potential biomarker for EGFR and glutaminase inhibition in mCRC, warranting further studies. These findings suggest opportunities to improve immune response and therapies in glutaminolysis-dependent tumors.
Authors
- Scott Kopetz (ORCID: https://orcid.org/0000-0001-9647-3416)
- John Paul Shen (ORCID: https://orcid.org/0000-0003-4588-2775)
- Cathy Eng (ORCID: https://orcid.org/0000-0003-2335-0612)
- Todd E. Peterson (ORCID: https://orcid.org/0000-0002-5951-7384)
- Dana B. Cardin (ORCID: https://orcid.org/0000-0002-0269-9615)
- Gregory D. Ayers (ORCID: https://orcid.org/0000-0002-0892-350X)
- Saikat Chowdhury (ORCID: https://orcid.org/0000-0002-0783-3959)
- Kangyu Lin (ORCID: https://orcid.org/0000-0003-0140-2557)
- Jordan Berlin (ORCID: https://orcid.org/0000-0001-7571-2385)
- Quanhu Sheng (ORCID: https://orcid.org/0000-0001-8951-9295)
- Kristen K. Ciombor (ORCID: https://orcid.org/0000-0002-5745-5909)
- Alexey V. Sorokin (ORCID: https://orcid.org/0000-0002-9682-8085)
- H. Charles Manning (ORCID: https://orcid.org/0000-0002-2042-8800)
- Yu Shyr (ORCID: https://orcid.org/0000-0003-2086-9670)
- Preeti Kanikarla Marie (ORCID: https://orcid.org/0000-0002-4913-8575)
- Jennifer G. Whisenant (ORCID: https://orcid.org/0000-0002-3435-2464)
- Seong-Woo Bae (ORCID: https://orcid.org/0000-0001-6530-3983)
- Laura W. Goff (ORCID: https://orcid.org/0000-0001-6719-1479)
- Gary T. Smith (ORCID: https://orcid.org/0000-0002-9235-4564)
- Allison S. Cohen
Institutions
- The University of Texas MD Anderson Cancer Center (US)
- Vanderbilt University (US)
- Washington University in St. Louis (US)
- Mallinckrodt (United States) (US)
- Vanderbilt University Medical Center (US)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2025-02-10
- DOI
- https://doi.org/10.1158/1078-0432.ccr-24-3133
- Citations
- 11
- Primary Topic
- Cancer, Hypoxia, and Metabolism
- Type
- article
- Field-Weighted Citation Impact
- 10.30
Funders
- Conquer Cancer Foundation
- Bristol-Myers Squibb
- Eli Lilly and Company
- AstraZeneca
- Cancer Prevention and Research Institute of Texas
- American College of Radiology Imaging Network
- Array BioPharma
- Exelixis
- Novocure
- Agios Pharmaceuticals
- BeiGene
- ECOG-ACRIN Cancer Research Group
- XBiotech
- Cardinal Health
- Relay Therapeutics
- Insmed
- Astellas Pharma
- Ipsen
- National Institutes of Health
- EMD Serono
- University of Texas MD Anderson Cancer Center
- National Cancer Institute